Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ceryvyn TherapeuticsCKDXF Equity-to-Asset is -3.54 as of Jun. 2025. The stock has 3 warning signs investors should review. Among 1,411 Biotechnology companies, Ceryvyn Therapeutics ranks worse than 96.6% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Ceryvyn Therapeutics's Total Stockholders Equity for the quarter that ended in Jun. 2025 was $-201.07 Mil. Ceryvyn Therapeutics's Total Assets for the quarter that ended in Jun. 2025 was $56.80 Mil.
Therefore, Ceryvyn Therapeutics's Equity to Asset Ratio for the quarter that ended in Jun. 2025 was -3.54.
The historical rank and industry rank for Ceryvyn Therapeutics's Equity-to-Asset or its related term are showing as below:
CKDXF'
s Equity-to-Asset Range Over the Past 10 Years
Min: -3.54 Med: 0.83 Max: 0.98
Current: -3.54
During the past 13 years, the highest Equity to Asset Ratio of Ceryvyn Therapeutics was 0.98. The lowest was -3.54. And the median was 0.83.
CKDXF's Equity-to-Asset is ranked worse than 96.6% of 1411
companies
in the Biotechnology industry
Industry Median: 0.68
vs CKDXF: -3.54
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Ceryvyn Therapeutics Equity-to-Asset Related Terms
Ceryvyn Therapeutics Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Ceryvyn Therapeutics's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CKDXF vs VRTX, REGN, RVMD: Equity-to-Asset Comparison
For the Biotechnology subindustry, Ceryvyn Therapeutics's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ceryvyn Therapeutics Equity-to-Asset vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Ceryvyn Therapeutics's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Ceryvyn Therapeutics's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Ceryvyn Therapeutics's Equity to Asset Ratio for the fiscal year that ended in Jun. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ceryvyn Therapeutics (CKDXF) has a Equity-to-Asset of -3.54 as of Jun. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ceryvyn Therapeutics and its competitors. According to the industry distribution chart, Ceryvyn Therapeutics ranks #1363 out of 1411 companies in the Biotechnology industry, placing it in the top 96.6%.
Is Ceryvyn Therapeutics' Equity-to-Asset too high?
Ceryvyn Therapeutics' current Equity-to-Asset is -3.54. Based on the distribution chart, Ceryvyn Therapeutics ranks #1363 out of 1411 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Ceryvyn Therapeutics' Equity-to-Asset compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Ceryvyn Therapeutics ranks #1363 out of 1411 companies for Equity-to-Asset. This places Ceryvyn Therapeutics in the lower half of its industry. The industry median Equity-to-Asset is 0.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Biotechnology company?
The median Equity-to-Asset among Biotechnology companies is 0.68, based on 1,411 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Ceryvyn Therapeutics and its competitors. For the Biotechnology industry, the median Equity-to-Asset is 0.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ceryvyn Therapeutics's current Equity-to-Asset is -3.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ceryvyn Therapeutics stock overvalued right now?
Ceryvyn Therapeutics (CKDXF) has a current Equity-to-Asset of -3.54. The current Equity-to-Asset is -3.54. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Ceryvyn Therapeutics (CKDXF), the current Equity-to-Asset is -3.54 as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Opthea Ltd is engaged in researching and developing novel therapeutic products that target Vascular Endothelial Growth Factors (VEGF) C, D, and R3. The Group operates in one industry and two geographical areas, namely biotechnology and healthcare, with operations in Australia and the United States. The company focuses on developing biological therapeutics for eye diseases and is currently developing a novel biologic therapy, OPT-302, for the treatment of eye conditions. Its products are based on an intellectual property portfolio covering VEGF-C, VEGF-D, and VEGF Receptor-3 targets, aimed at treating diseases associated with blood and lymphatic vessel growth and vascular leakage.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CKDXF has been successfully added to your 
